A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 3, 2002, Pages 479-485

  Holtmann, G ^a   Bytzer, P ^b   Metz, M ^c   Loeffler, V ^c   Blum, A L ^d  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c Eisai GmbH   (Germany)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; OMEPRAZOLE; RABEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; ENDOSCOPY; ESOPHAGITIS; ESOPHAGUS INJURY; FEMALE; GASTROESOPHAGEAL REFLUX; HEALING; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; TREATMENT OUTCOME;

EID: 0036191747     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01207.x     Document Type: Article

References (20)

1. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms
2. Short-term treatment with proton pump inhibitors. H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease -like symptoms and endoscopy negative reflux disease (Cochrane Review)
3. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients
4. Overview of medical therapy for gastroesophageal reflux disease
5. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease
6. Rabeprazole
7. Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease
8. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease
9. Rabeprazole in treatment of acid peptic diseases: Results of three placebo -controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD)
10. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease
11. Rabeprazole: Preventing endoscopic and symptomatic relapse in erosive or ulcerative GERD
12. Identification of the characteristics influencing the degree of antisecretory activity of PPIs
13. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects
14. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The U.S. Multicenter study
15. Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis
16. Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study
17. Long-term management of gastroesophageal reflux disease
18. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice
19. Long-term prescribing of proton pump inhibitors in general practice
20. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease